EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of clinicopathological features and survival in triple-negative and non-triple-negative breast cancer patients in Tanzania

Eulade Rugengamanzi iD, Nazima Dharsee iD, Emmanuel L Lugina iD, Jesse Jonathan Kashabano, Gad Murenzi iD, Alan Paciorek, Godfrey Malangwa, Mathias Banzi, Glory Makupa, Godwin Nnko, Leila Mwakipunda, Amie Y Lee

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf345 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Oncologist, 2025. Verfasst von Eulade Rugengamanzi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, Building a Cancer Research Training Program in Tanzania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Breast cancer is a heterogeneous disease with a wide spectrum of subtypes, each with distinct biological features. Data on tumor subtypes in East Africa are sparse despite the rising incidence of breast cancer in this region. We aimed to determine the prevalence of triple-negative breast cancer (TNBC) and to compare clinicopathological features, overall survival (OS), and factors affecting OS of patients with TNBC and non-TNBC in Tanzania.

Methods

This retrospective nested case–control study included patients with histologically proven breast cancer treated at Ocean Road Cancer Institute (ORCI) in Tanzania from January 2018 to December 2019. Logistic regression was used to determine factors associated with TNBC, and Cox proportional hazards regression was used to determine the factors independently associated with overall survival.

Results

TNBC constituted 23.3% of all breast cancer diagnoses. Patients in the TNBC group were younger (median age 46 vs 53 years, P < .001) and more often presented with stage IV disease (12% vs 4%, P = .001). Three-year OS was significantly lower in the TNBC group (36%) compared to the non-TNBC group (57%) (P = .004) and remained lower for the TNBC group across every tumor stage. Brain metastasis was higher in the TNBC group (34% vs 7%, P < .001). Factors associated with improved survival included shorter symptom duration (0.53 [0.36-0.78]), earlier stage (0.23 [0.12-0.46]), use of neoadjuvant chemotherapy (0.59 [0.40-0.86]), and surgery with clean margins (0.34 [0.19-0.60]).

Conclusions

TNBC accounted for nearly a quarter of the breast cancers at ORCI. TNBC was associated with younger age, more aggressive clinicopathologic features, and worse survival. Efforts toward earlier diagnosis and optimized therapies will be critical to improving TNBC outcomes in Tanzania.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHumansFemaleTanzaniaMiddle AgedRetrospective StudiesCase-Control StudiesAdultAgedSurvival RatePrognosis

Stichwörter der Autor:innen

breast cancer subtypesoverall survivalsub-Saharan Africatriple-negative breast cancer (TNBC)

Autor:innen und Institutionen

  • Academic, Research, and Consultancy Unit, Ocean Road Cancer Institute, Dar es Salaam, Tanzania.
  • Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • Department of Oncology, The Butaro Cancer Center of Excellence, Butaro, Rwanda.
  • Clinical Division, Medical School, University of Global Health Equity (UGHE), Butaro, Rwanda.
  • Einstein-Rwanda Research and Capacity Building Program, Research for Development (RD Rwanda), Kigali, Rwanda.
  • Oncology departement, Benjamin Mkapa Hospital, Dodoma, Tanzania.

ORCID-Profile: Eulade Rugengamanzi, Nazima Dharsee, Emmanuel L Lugina, Gad Murenzi

Förderung

  • FIC NIH HHS
  • Building a Cancer Research Training Program in Tanzania

Zitieren

APA

Rugengamanzi, E., Dharsee, N., Lugina, E. L., Kashabano, J. J., Murenzi, G., Paciorek, A., Malangwa, G., Banzi, M., Makupa, G., Nnko, G., Mwakipunda, L., & Lee, A. Y. (2025). Comparison of clinicopathological features and survival in triple-negative and non-triple-negative breast cancer patients in Tanzania. The Oncologist. https://doi.org/10.1093/oncolo/oyaf345

Vancouver

Rugengamanzi E, Dharsee N, Lugina EL, Kashabano JJ, Murenzi G, Paciorek A, et al. Comparison of clinicopathological features and survival in triple-negative and non-triple-negative breast cancer patients in Tanzania. The Oncologist. 2025. doi:10.1093/oncolo/oyaf345

BibTeX
@article{Rugengamanzi2025,
  author = {Rugengamanzi, Eulade and Dharsee, Nazima and Lugina, Emmanuel L and Kashabano, Jesse Jonathan and Murenzi, Gad and Paciorek, Alan and Malangwa, Godfrey and Banzi, Mathias and Makupa, Glory and Nnko, Godwin and Mwakipunda, Leila and Lee, Amie Y},
  title = {Comparison of clinicopathological features and survival in triple-negative and non-triple-negative breast cancer patients in Tanzania},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf345}
}
Kostenlos starten →